G Helbig

Summary

Affiliation: Medical University
Country: Poland

Publications

  1. ncbi request reprint Diagnostic and therapeutic management in patients with hypereosinophilic syndromes
    Grzegorz Helbig
    Department of Hematology and Bone Marrow Transplantation, Medical University of Silesia, Katowice, Poland
    Pol Arch Med Wewn 121:44-52. 2011
  2. pmc Rituximab is highly effective for pure red cell aplasia and post-transplant lymphoproliferative disorder after unrelated hematopoietic stem cell transplantation
    Anna Kopinska
    Department of Hematology and Bone Marrow Transplantation, Silesian Medical University, Katowice, Poland
    Contemp Oncol (Pozn) 16:215-7. 2012
  3. doi request reprint Characteristics and clinical outcome of patients with hypereosinophilia of undetermined significance
    Grzegorz Helbig
    Department of Hematology and Bone Marrow Transplantation, Silesian Medical University, Dabrowski Street 25, 40 032, Katowice, Poland
    Med Oncol 31:815. 2014
  4. doi request reprint Diversity of clinical manifestations and response to corticosteroids for idiopathic hypereosinophilic syndrome: retrospective study in 33 patients
    Grzegorz Helbig
    Department of Hematology and Bone Marrow Transplantation, Silesian Medical University, Katowice, Poland
    Leuk Lymphoma 54:807-11. 2013
  5. doi request reprint The JAK2V617F tyrosine kinase mutation has no impact on overall survival and the risk of leukemic transformation in myelofibrosis
    Grzegorz Helbig
    Department of Hematology and Bone Marrow Transplantation, Silesian Medical University, Dabrowski Street 25, 40 032, Katowice, Poland
    Med Oncol 29:2379-84. 2012
  6. doi request reprint Chronic eosinophilic leukemia-not otherwise specified has a poor prognosis with unresponsiveness to conventional treatment and high risk of acute transformation
    Grzegorz Helbig
    Department of Hematology and Bone Marrow Transplantation, Silesian Medical University, Katowice, Poland
    Am J Hematol 87:643-5. 2012
  7. doi request reprint Imatinib mesylate may induce long-term clinical response in FIP1L1-PDGFRα-negative hypereosinophilic syndrome
    Grzegorz Helbig
    Department of Haematology and Bone Marrow Transplantation, Silesian Medical University, Dabrowski Street 25, 40 032, Katowice, Poland
    Med Oncol 29:1073-6. 2012
  8. doi request reprint Irreversible marrow aplasia after single course of 2-chlorodeoxyadenosine for hairy cell leukaemia preceding by A pandemic 2009-H1N1-associated pneumonia
    Grzegorz Helbig
    Department of Haematology and Bone Marrow Transplantation, Silesian Medical University, Dabrowski Street 25, 40 032, Katowice, Poland
    Med Oncol 28:1601-3. 2011
  9. pmc T-cell abnormalities are present at high frequencies in patients with hypereosinophilic syndrome
    Grzegorz Helbig
    Department of Haematology and Bone Marrow Transplantation, Silesian Medical University, Dabrowski Street 25, Katowice, Poland
    Haematologica 94:1236-41. 2009
  10. ncbi request reprint Clinical characteristics of patients with chronic eosinophilic leukaemia (CEL) harbouring FIP1L1-PDGFRA fusion transcript--results of Polish multicentre study
    Grzegorz Helbig
    Departament of Haematology and Bone Marrow Transplantation, Silesian Medical University, Katowice, Poland
    Hematol Oncol 28:93-7. 2010

Detail Information

Publications21

  1. ncbi request reprint Diagnostic and therapeutic management in patients with hypereosinophilic syndromes
    Grzegorz Helbig
    Department of Hematology and Bone Marrow Transplantation, Medical University of Silesia, Katowice, Poland
    Pol Arch Med Wewn 121:44-52. 2011
    ..This review reflects the current state of knowledge on the pathogenesis and therapy of HES. The shortcomings of current definitions and classifications are also discussed...
  2. pmc Rituximab is highly effective for pure red cell aplasia and post-transplant lymphoproliferative disorder after unrelated hematopoietic stem cell transplantation
    Anna Kopinska
    Department of Hematology and Bone Marrow Transplantation, Silesian Medical University, Katowice, Poland
    Contemp Oncol (Pozn) 16:215-7. 2012
    ..This is the first report on an adult patient who simultaneously developed PRCA and PTLD after ABO-mismatched AlloHSCT. The early introduction of rituximab resulted in prompt resolution of clinical symptoms with subsequent full recovery. ..
  3. doi request reprint Characteristics and clinical outcome of patients with hypereosinophilia of undetermined significance
    Grzegorz Helbig
    Department of Hematology and Bone Marrow Transplantation, Silesian Medical University, Dabrowski Street 25, 40 032, Katowice, Poland
    Med Oncol 31:815. 2014
    ..One patient developed hypereosinophilic syndrome (HES) after 11 years of follow-up. Further studies are needed to define risk factors of HES development. The use of CS for HEus patients is controversial and should be individualized...
  4. doi request reprint Diversity of clinical manifestations and response to corticosteroids for idiopathic hypereosinophilic syndrome: retrospective study in 33 patients
    Grzegorz Helbig
    Department of Hematology and Bone Marrow Transplantation, Silesian Medical University, Katowice, Poland
    Leuk Lymphoma 54:807-11. 2013
    ..Seven patients (21%) were resistant or intolerant to CS. Five patients (15%) achieved a 50% reduction of blood eosinophilia. In conclusion, CS were found to be highly effective in IHES with manageable side effects...
  5. doi request reprint The JAK2V617F tyrosine kinase mutation has no impact on overall survival and the risk of leukemic transformation in myelofibrosis
    Grzegorz Helbig
    Department of Hematology and Bone Marrow Transplantation, Silesian Medical University, Dabrowski Street 25, 40 032, Katowice, Poland
    Med Oncol 29:2379-84. 2012
    ..03). Median follow-ups for V617F-positive and V617F-negative patients were 16.6 months (range 3.6-206.4) and 36.4 months (range 2.5-142.1), respectively. The presence of JAK2V617F mutation did not affect OS and the risk of LT development...
  6. doi request reprint Chronic eosinophilic leukemia-not otherwise specified has a poor prognosis with unresponsiveness to conventional treatment and high risk of acute transformation
    Grzegorz Helbig
    Department of Hematology and Bone Marrow Transplantation, Silesian Medical University, Katowice, Poland
    Am J Hematol 87:643-5. 2012
    ..Except the latter patient, imatinib was ineffective in our study population. CEL-NOS is a rare and aggressive disease with high rate of AT and resistance to conventional treatment...
  7. doi request reprint Imatinib mesylate may induce long-term clinical response in FIP1L1-PDGFRα-negative hypereosinophilic syndrome
    Grzegorz Helbig
    Department of Haematology and Bone Marrow Transplantation, Silesian Medical University, Dabrowski Street 25, 40 032, Katowice, Poland
    Med Oncol 29:1073-6. 2012
    ..Our results suggest that IM, even at lower than conventional doses, may induce and maintain long-term remission for FIP1L1-PDGFRα-negative HES...
  8. doi request reprint Irreversible marrow aplasia after single course of 2-chlorodeoxyadenosine for hairy cell leukaemia preceding by A pandemic 2009-H1N1-associated pneumonia
    Grzegorz Helbig
    Department of Haematology and Bone Marrow Transplantation, Silesian Medical University, Dabrowski Street 25, 40 032, Katowice, Poland
    Med Oncol 28:1601-3. 2011
    ..The subsequent treatment with single 5-day course of 2-CdA resulted in persistent marrow aplasia with fatal systemic aspergillosis...
  9. pmc T-cell abnormalities are present at high frequencies in patients with hypereosinophilic syndrome
    Grzegorz Helbig
    Department of Haematology and Bone Marrow Transplantation, Silesian Medical University, Dabrowski Street 25, Katowice, Poland
    Haematologica 94:1236-41. 2009
    ....
  10. ncbi request reprint Clinical characteristics of patients with chronic eosinophilic leukaemia (CEL) harbouring FIP1L1-PDGFRA fusion transcript--results of Polish multicentre study
    Grzegorz Helbig
    Departament of Haematology and Bone Marrow Transplantation, Silesian Medical University, Katowice, Poland
    Hematol Oncol 28:93-7. 2010
    ..Our study confirmed the long-term remission on imatinib in this patient population...
  11. ncbi request reprint Pure red-cell aplasia following major and bi-directional ABO-incompatible allogeneic stem-cell transplantation: recovery of donor-derived erythropoiesis after long-term treatment using different therapeutic strategies
    Grzegorz Helbig
    Department of Haematology and Bone Marrow Transplantation, Silesian Medical University, Reymont Street 8, 40 027 Katowice, Poland
    Ann Hematol 86:677-83. 2007
    ..Major ABO mismatch may lead to delayed donor erythroid engraftment. It results in long-term transfusion dependence and, therefore, the risk of iron overload. The therapy is long lasting, but usually effective in majority of patients...
  12. ncbi request reprint Interferon alpha induces a good molecular response in a patient with chronic eosinophilic leukemia (CEL) carrying the JAK2V617F point mutation
    G Helbig
    Departament of Haematology and Bone Marrow Transplantation, Silesian Medical University, 40 027 Katowice, Dabrowski str 25, Poland
    Haematologica 92:e118-9. 2007
    ..The molecular response correlated with only moderate haematological improvement...
  13. doi request reprint A single weekly dose of imatinib is sufficient to induce and maintain remission of chronic eosinophilic leukaemia in FIP1L1-PDGFRA-expressing patients
    Grzegorz Helbig
    Department of Haematology and Bone Marrow Transplantation, Silesian Medical University, Katowice, Poland
    Br J Haematol 141:200-4. 2008
    ..These data suggest that a single weekly dose of imatinib is sufficient to maintain remission in FIP1L1-PDGFRA- positive CEL patients...
  14. ncbi request reprint Successful treatment of pure red cell aplasia with repeated, low doses of rituximab in two patients after ABO-incompatible allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia
    Grzegorz Helbig
    Department of Haematology and BMT, Silesian Medical University, Katowice, Poland
    Haematologica 90:ECR33. 2005
    ..We observed rapid recovery from PRCA without any side effects. We conclude that rituximab seems to be a promising therapeutic option in patients with PRCA after ABO-mismatched HSCT, in whom conventional treatment fails...
  15. ncbi request reprint Elastin metabolism is disrupted in patients after allogeneic hematopoietic stem cell transplantation (alloHSCT) for acute and chronic myeloid leukemia
    Grzegorz Helbig
    Department of Hematology and Bone Marrow Transplantation, Silesian Medical University, Katowice, Poland
    Med Sci Monit 14:CR584-8. 2008
    ..The objective of the study was to evaluate elastin metabolism before and at two time-points after HSCT...
  16. ncbi request reprint Immunogenic disparities of 11 minor histocompatibility antigens (mHAs) in HLA-matched unrelated allogeneic hematopoietic SCT
    M Markiewicz
    Department of Hematology and Bone Marrow Transplantation, Medical University of Silesia, Dabrowskiego 25, Katowice, Poland
    Bone Marrow Transplant 43:293-300. 2009
    ....
  17. ncbi request reprint The results of imatinib therapy for patients with primary eosinophilic disorders
    Grzegorz Helbig
    Eur J Haematol 76:535-6. 2006
  18. ncbi request reprint [Oncogene Fip1-likeL/PDGFRalpha as a target for imatinib in patients with hypereosinophilic syndrome and chronic eosinophilic leukemia. A novel look at pathogenesis and therapy]
    Grzegorz Helbig
    Katedra i Klinika Hematologii i Transplantacji Szpiku Si AM w Katowicach
    Pol Arch Med Wewn 113:490-7. 2005
  19. ncbi request reprint [Ras signaling pathway as a target for farnesyltransferase inhibitors--a new, promising prospects in the treatment for malignant disorders]
    Grzegorz Helbig
    Katedry i Kliniki Hematologii i Transplantacji Szpiku, Slaskiej Akademii Medycznej w Katowicach
    Wiad Lek 57:462-7. 2004
    ..The II phase trials with FTI are under way and we hope, that these agents will find an unquestionable position in treatment of patients with malignancies...